Mérieux Développement, the investment arm of the French biotech conglomerate Institut Mérieux, has led a $6.4m financing round for NeuroPhage, a life sciences company. Existing investors Shire Pharmaceuticals also joined the round, which takes the total funding raised by the company to $35m. Neurophage is developing treatments for neurodegenerative diseases, including Alzheimer’s, Parkinson’s and Huntington’s…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
